Cancer: And the Blood Test That Could SAVE Your Life

Cancer.

It’s a word that strikes fear into the hearts of millions, a devastating diagnosis that can turn lives upside down in an instant.

For far too many, the battle against this insidious disease begins only after it has already taken hold, when treatment options are limited and the odds of survival are stacked against them.

But what if there was a way to detect cancer long before symptoms appear? To catch it at its earliest stages when the chances of successful treatment are at their highest?

Two groundbreaking studies from Oxford Population Health offer a glimmer of hope in the fight against this relentless foe.

The studies, published in Nature Communications, have identified an astonishing 618 proteins in the blood that could warn people of cancer more than seven years before a formal diagnosis.

Using a powerful technique called proteomics, scientists analyzed blood samples from over 44,000 people, including nearly 5,000 who later received a cancer diagnosis.

By comparing the proteins found in the blood of those who did and did not go on to develop cancer, the researchers were able to pinpoint 107 proteins that were present in the blood at least seven years before a diagnosis.

These proteins, they believe, could be involved in the very earliest stages of cancer development, offering an unprecedented opportunity for early detection and prevention.

The implications of this discovery are profound. Imagine a world where a simple blood test could warn you of a brewing cancer years before any symptoms appear, giving you the chance to take proactive steps to protect your health.

With earlier detection comes the possibility of earlier intervention, of catching cancer before it has a chance to take root and spread.

But the researchers didn’t stop there. In a second study, they delved even deeper, using genetic data from over 300,000 cancer cases to identify 40 proteins in the blood that directly influence a person’s risk of developing nine different types of cancer.

While altering these proteins may increase or decrease cancer risk, the scientists caution that doing so could also lead to unintended side effects, underscoring the need for further research.

Dr. Keren Papier, Senior Nutritional Epidemiologist at Oxford Population Health and joint first author of the first study, emphasizes the importance of understanding the earliest stages of cancer development. “To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease,” she says. “Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer. Now we need to study these proteins in depth to see which ones could be reliably used for prevention.”

The road ahead is long, and many questions remain.

Which of these proteins are the most reliable indicators of cancer risk? What tests could be developed to detect them in a clinical setting? Which drugs could target these proteins to prevent or slow the development of cancer?

These are the challenges that researchers now face as they work to translate these groundbreaking findings into tangible benefits for patients.

But for the millions of people living in the shadow of cancer, for the families and loved ones who have watched helplessly as this disease claims far too many lives, this type of knowledge is power.

And with each new discovery, each new insight into the complex workings of this disease, we arm ourselves with the tools we need to detect it earlier, treat it more effectively, and one day, perhaps, prevent it altogether.

To a future free from the fear of cancer,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Everyday products linked to breast cancer? (Here’s how to safeguard your health.)

Sources:

“Identifying proteomic risk factors for cancer using prospective and exome analyses of 1,463 circulating proteins and risk of 19 cancers in the UK Biobank.” Nature Communications (2024). www.nature.com/articles/s41467-024-48017-6

Karl Smith-Byrne et al. “Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers.” Nature Communications (2024). DOI: 10.1038/s41467-024-46834-3